Scott J. Antonia, MD, PhD

BOARD CERTIFICATION:
          •  Medical Oncology

FELLOWSHIP:
          •  Yale University of School of Medicine - Immunology
          •  Yale University of School of Medicine - Medical Oncology

RESIDENCY:
          •  Yale-New Haven Hospital - Internal Medicine

MEDICAL SCHOOL:
          •  University of Connecticut Health Center - MD

• Gonzalez LE, Sutton SK, Pratt C, Gilbertson M, Antonia S, Quinn GP. The Bottleneck Effect in Lung Cancer Clinical Trials. J Cancer Educ. 2013 Jun. Pubmedid: 23733149.


• Soliman H, Rawal B, Fulp J, Lee JH, Lopez A, Bui MM, Khalil F, Antonia S, Yfantis HG, Lee DH, Dorsey TH, Ambs S. Analysis of indoleamine 2-3 dioxygenase (IDO1) expression in breast cancer tissue by immunohistochemistry. Cancer Immunol Immunother. 2013 May;62(5):829-837. Pubmedid: 23344392.


• Bepler G, Williams C, Schell MJ, Chen W, Zheng Z, Simon G, Gadgeel S, Zhao X, Schreiber F, Brahmer J, Chiappori A, Tanvetyanon T, Pinder-Schenck M, Gray J, Haura E, Antonia S, Fischer JR. Randomized International Phase III Trial of ERCC1 and RRM1 Expression-Based Chemotherapy Versus Gemcitabine/Carboplatin in Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2013 May. Pubmedid: 23690416.


• Iclozan C, Antonia S, Chiappori A, Chen DT, Gabrilovich D. Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol Immunother. 2013 May;62(5):909-918. Pubmedid: 23589106.


• Hopewell EL, Zhao W, Fulp WJ, Bronk CC, Lopez AS, Massengill M, Antonia S, Celis E, Haura EB, Enkemann SA, Chen DT, Beg AA. Lung tumor NF-?B signaling promotes T cell-mediated immune surveillance. J Clin Invest. 2013 May;123(6):2509-2522. Pubmedid: 23635779.


• Youn JI, Kumar V, Collazo M, Nefedova Y, Condamine T, Cheng P, Villagra A, Antonia S, McCaffrey JC, Fishman M, Sarnaik A, Horna P, Sotomayor E, Gabrilovich DI. Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nat Immunol. 2013 Mar;14(3):211-220. Pubmedid: 23354483. Pmcid: PMC3578019.


• McBride A, Antonia SJ, Haura EB, Goetz D. Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase g2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature. J Pharm Pract. 2012 Aug;25(4):477-485. Pubmedid: 22550162.


• Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012 Jun;366(26):2443-2454. Pubmedid: 22658127. Pmcid: PMC3544539.


• Simon GR, Schell MJ, Begum M, Kim J, Chiappori A, Haura E, Antonia S, Bepler G. Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis. Cancer. 2012 Jun;118(9):2525-2531. Pubmedid: 22028294. Pmcid: PMC3270127.


• Finkelstein SE, Rodriguez F, Dunn M, Farmello MJ, Smilee R, Janssen W, Kang L, Chuang T, Seigne J, Pow-Sang J, Torres-Roca JF, Heysek R, Biagoli M, Shankar R, Scott J, Antonia S, Gabrilovich D, Fishman M. Serial assessment of lymphocytes and apoptosis in the prostate during coordinated intraprostatic dendritic cell injection and radiotherapy. Immunotherapy. 2012 Apr;4(4):373-382. Pubmedid: 22512631.


• Finkelstein SE, Fishman M, Conley AP, Gabrilovich D, Antonia S, Chiappori A. Cellular immunotherapy for soft tissue sarcomas. Immunotherapy. 2012 Mar;4(3):283-290. Pubmedid: 22401634.


• Finkelstein SE, Iclozan C, Bui MM, Cotter MJ, Ramakrishnan R, Ahmed J, Noyes DR, Cheong D, Gonzalez RJ, Heysek RV, Berman C, Lenox BC, Janssen W, Zager JS, Sondak VK, Letson GD, Antonia SJ, Gabrilovich DI. Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients. Int J Radiat Oncol Biol Phys. 2012 Feb;82(2):924-932. Pubmedid: 21398051.


• Mahmood ST, Agresta S, Vigil C, Zhao X, Han G, D'Amato G, Calitri CE, Dean M, Garrett C, Schell MJ, Antonia S, Chiappori A. Phase II study of sunitinib malate, a multi-targeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on 3 prevalent histologies: Leiomyosarcoma, liposarcoma, and malignant fibrous histiocytoma. Int J Cancer. 2011 Oct;129(8):1963-1969. Pubmedid: 21154746.


• Hunter TB, Manimala NJ, Luddy KA, Catlin T, Antonia SJ. Paclitaxel and TRAIL synergize to kill paclitaxel-resistant small cell lung cancer cells through a caspase-independent mechanism mediated through AIF. Anticancer Res. 2011 Oct;31(10):3193-3204. Pubmedid: 21965726.


• Riddle ND, Gonzalez RJ, Bridge JA, Antonia S, Bui MM. A CD117 and CD34 immunoreactive sarcoma masquerading as a gastrointestinal stromal tumor: diagnostic pitfalls of ancillary studies in sarcoma. Cancer Control. 2011 Jul;18(3):152-159. Pubmedid: 21666577.


• R?ter J, Antonia SJ, Burris HA, Huhn RD, Vonderheide RH. Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors. Cancer Biol Ther. 2011 Mar;10(10):983-993. Pubmedid: 20855968. Pmcid: PMC3047092.


• Finkelstein SE, Carey T, Fricke I, Yu D, Goetz D, Gratz M, Dunn M, Urbas P, Daud A, DeConti R, Antonia S, Gabrilovich D, Fishman M. Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer and melanoma. J Immunother. 2010 Oct;33(8):817-827. Pubmedid: 20842055.


• Herber DL, Cao W, Nefedova Y, Novitskiy SV, Nagaraj S, Tyurin VA, Corzo A, Cho HI, Celis E, Lennox B, Knight SC, Padhya T, McCaffrey TV, McCaffrey JC, Antonia S, Fishman M, Ferris RL, Kagan VE, Gabrilovich DI. Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med. 2010 Aug;16(8):880-886. Pubmedid: 20622859. Pmcid: PMC2917488.


• Soliman H, Mediavilla-Varela M, Antonia S. Indoleamine 2,3-dioxygenase: is it an immune suppressor?. Cancer J. 2010 July;16(4):354-359. Pubmedid: 20693847.


• Chiappori AA, Soliman H, Janssen WE, Antonia SJ, Gabrilovich DI. INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. Expert Opin Biol Ther. 2010 Jun;10(6):983-991. Pubmedid: 20420527. Pmcid: PMC3146364.


• Demetri GD, Antonia S, Benjamin RS, Bui MM, Casper ES, Conrad EU, DeLaney TF, Ganjoo KN, Heslin MJ, Hutchinson RJ, Kane JM, Letson GD, McGarry SV, O'Donnell RJ, Paz IB, Pfeifer JD, Pollock RE, Randall RL, Riedel RF, Schupak KD, Schwartz HS, Thornton K, von Mehren M, Wayne J. Soft tissue sarcoma. J Natl Compr Canc Netw. 2010 Jun;8(6):630-674. Pubmedid: 20581298.


• Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S, Gray J, Litschauer S, Tetteh L, Neuger A, Song L, Rawal B, Schell MJ, Bepler G. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol. 2010 Apr;28(8):1387-1394. Pubmedid: 20142592. Pmcid: PMC3040065.


• Ramakrishnan R, Assudani D, Nagaraj S, Hunter T, Cho HI, Antonia S, Altiok S, Celis E, Gabrilovich DI. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest. 2010 Apr;120(4):1111-1124. Pubmedid: 20234093. Pmcid: PMC2846048.


• Giglia JL, Antonia SJ, Berk LB, Bruno S, Dessureault S, Finkelstein SE. Systemic therapy for advanced hepatocellular carcinoma: past, present, and future. Cancer Control. 2010 Apr;17(2):120-129. Pubmedid: 20404795.


• Nagaraj S, Youn JI, Weber H, Iclozan C, Lu L, Cotter MJ, Meyer C, Becerra CR, Fishman M, Antonia S, Sporn MB, Liby KT, Rawal B, Lee JH, Gabrilovich DI. Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clin Cancer Res. 2010 Mar;16(6):1812-1823. Pubmedid: 20215551. Pmcid: PMC2840181.


• Bui MM, Zheng Z, Antonia S, Bepler G. Thymidylate synthase 1 (TS1) in-situ protein expression predicts the survival of Ewing/PNET. Fetal Pediatr Pathol. 2010;29(6):385-392. Pubmedid: 21043562. Pmcid: PMC3568950.


• Ortega J, Hayes JM, Antonia S. Hepatic portal venous gas in a patient with metastatic non-small cell lung cancer on bevacizumab therapy: a case report and review of the literature. Cancer Chemother Pharmacol. 2009 Oct;65(1):187-190. Pubmedid: 19697030.


• Camacho LH, Antonia S, Sosman J, Kirkwood JM, Gajewski TF, Redman B, Pavlov D, Bulanhagui C, Bozon VA, Gomez-Navarro J, Ribas A. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol. 2009 Mar;27(7):1075-1081. Pubmedid: 19139427.


• Tolcher AW, Mita A, Lewis LD, Garrett CR, Till E, Daud AI, Patnaik A, Papadopoulos K, Takimoto C, Bartels P, Keating A, Antonia S. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol. 2008 Nov;26(32):5198-5203. Pubmedid: 18824702.


• Bepler G, Sommers KE, Cantor A, Li X, Sharma A, Williams C, Chiappori A, Haura E, Antonia S, Tanvetyanon T, Simon G, Obasaju C, Robinson LA. Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. J Thorac Oncol. 2008 Oct;3(10):1112-1118. Pubmedid: 18827606. Pmcid: PMC2639211.


• Ramakrishnan R, Antonia S, Gabrilovich D. Combined modality immunotherapy and chemotherapy: a new perspective. Cancer Immunol Immunother. 2008 Oct;57(10):1523-1529. Pubmedid: 18488219.


• Simon GR, Extermann M, Chiappori A, Williams CC, Begum M, Kapoor R, Haura EB, Ismail-Khan R, Schell MJ, Antonia SJ, Bepler G. Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older. Cancer. 2008 May;112(9):2021-2029. Pubmedid: 18300255.


• Chiappori AA, Haura E, Rodriguez FA, Boulware D, Kapoor R, Neuger AM, Lush R, Padilla B, Burton M, Williams C, Simon G, Antonia S, Sullivan DM, Bepler G. Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer. Clin Cancer Res. 2008 Mar;14(5):1464-1469. Pubmedid: 18316570.


• Fishman M, Hunter T, Soliman H, Thompson P, Dunn M, Smilee R, Farmelo M, Noyes D, Mahany J, Lee J, Cantor A, Messina J, Seigne J, Pow-Sang J, JanssenW, Antonia S. Phase II Trial of B7-1 (CD-86) Transduced, Cultured Autologous Tumor Cell Vaccine Plus Subcutaneous Interleukin-2 for Treatment of Stage IV Renal Cell Carcinoma. J Immunother (1997). 2008 Jan;31(1):72-80. Pubmedid: 18157014.


• Simon G, Sharma A, Li X, Hazelton T, Walsh F, Williams C, Chiappori A, Haura E, Tanvetyanon T, Antonia S, Cantor A, Bepler G. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol. 2007 Jul;25(19):2741-2746. Pubmedid: 17602079.


• Hunter T, Alsarraj M, Gladue R, Bedian V, Antonia S. An Agonist Antibody Specific for CD40 Induces Dendritic Cell Maturation and Promotes Autologous Anti-tumour T-cell Responses in an In vitro Mixed Autologous Tumour Cell/Lymph Node Cell Model. Scand J Immunol. 2007 May;65(5):479-486. Pubmedid: 17444959.


• de Lima Lopes G, Chiappori A, Simon G, Haura E, Sullivan D, Antonia S, Langevin M, Lush R, Rocha-Lima CM. Phase I study of carboplatin in combination with gemcitabine and irinotecan in patients with solid tumors: preliminary evidence of activity in small cell and neuroendocrine carcinomas. Cancer. 2007 Apr;109(7):1413-1419. Pubmedid: 17326096.


• Vonderheide R, Flaherty K, Khalil M, Stumacher M, Bajor D, Hutnick N, Sullivan P, Mahany J, Gallagher M, Kramer A, Green S, O'Dwyer P, Running K, Huhn R, Antonia S. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol. 2007 Mar;25(7):876-883. Pubmedid: 17327609.


• Dessureault S, Noyes D, Lee D, Dunn M, Janssen W, Cantor A, Sotomayor E, Messina J, Antonia S. A phase-I Trial Using a Universal GM-CSF-producing and CD40L-expressing Bystander Cell Line (GM.CD40L) in the Formulation of Autologous Tumor Cell-based Vaccines for Cancer Patients with Stage IV disease. Ann Surg Oncol. 2007 Feb;14(2):869-884. Pubmedid: 17103257.


• Mirza N, Fishman M, Fricke I, Dunn M, Neuger AM, Frost TJ, Lush RM, Antonia S, Gabrilovich DI. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res. 2006 Sep;66(18):9299-9307. Pubmedid: 16982775. Pmcid: PMC1586106.


• Ohashi K, Kobayashi G, Fang S, Zhu X, Antonia SJ, Krieg AM, Sandler AD. Surgical excision combined with autologous whole tumor cell vaccination is an effective therapy for murine neuroblastoma. J Pediatr Surg. 2006 Aug;41(8):1361-1368. Pubmedid: 16863838.


• Simon G, Lush R, Gump J, Tetteh L, Williams C, Cantor A, Antonia S, Garrett C, Rocha-Lima C, Fishman M, Sullivan D, Munster P. Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial. Mol Cancer Ther. 2006 Aug;5(8):2130-2137. Pubmedid: 16928835.


• Antonia S, Mirza N, Fricke I, Chiappori A, Thompson P, Williams N, Bepler G, Simon G, Janssen W, Lee J, Menander K, Chada S, Gabrilovich D. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res. 2006 Feb;12(3 Pt1):878-887. Pubmedid: 16467102.


• Chiappori A, Simon G, Williams C, Haura E, Rocha-Lima C, Wagner H, Bepler G, Antonia S. Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer. Oncology-Basel. 2005 Sep;68(4-6):382-390. Pubmedid: 16020967.


• Dessureault S, Alsarraj M, McCarthy S, Hunter T, Noyes D, Lee D, Harkins J, Seigne J, Jennings R, Antonia S. A GM-CSF/CD40L producing cell augments anti-tumor T cell responses. J Surg Res. 2005 May;125(2):173-181. Pubmedid: 15854671.


• Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ, Messina JL, Chandler P, Koni PA, Mellor AL. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest. 2004 Jul;114(2):280-290. Pubmedid: 15254595. Pmcid: PMC449750.


• Fishman M, Antonia S. Specific antitumour vaccine for renal cancer. Lancet. 2004;363(9409):583-584. Pubmedid: 14987879.


• Rodriguez P, Quiceno D, Zabaleta J, Ortiz B, Zea A, Piazuelo M, Delgado A, Correa P, Brayer J, Sotomayor E, Antonia S, Ochoa J, Ochoa A. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 2004;64(16):5839-5849. Pubmedid: 15313928.


• Antonia S, Mule J, Weber J. Current developments of immunotherapy in the clinic. Curr Opin Immunol. 2004;16(2):130-136. Pubmedid: 15023403.


• Lee JR, Dalton RR, Messina JL, Sharma MD, Smith DM, Burgess RE, Mazzella F, Antonia SJ, Mellor AL, Munn DH. Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. Lab Invest. 2003 Oct;83(10):1457-1466. Pubmedid: 14563947.


• Haura EB, Sotomayor E, Antonia SJ. Gene therapy for lung cancer. Mol Biotechnol. 2003 Oct;25(2):139-148. Pubmedid: 14526124.


• Haura EB, Sotomayor E, Antonia SJ. Gene therapy for lung cancer. An introduction. Methods Mol Med. 2003;75:529-543. Pubmedid: 12407762.


• Fishman M, Antonia S. Cell-based immune therapy for metastatic renal cancer. Expert Rev Anticancer Ther. 2003;3(6):837-849. Pubmedid: 14686706.


• Fishman M, Antonia S. Novel therapies for renal cell carcinoma - an update. Expert Opin Investig Drugs. 2003;12(4):593-609. Pubmedid: 12665415.


• Munn DH, Sharma MD, Lee JR, Jhaver KG, Johnson TS, Keskin DB, Marshall B, Chandler P, Antonia SJ, Burgess R, Slingluff CL , Mellor AL. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science. 2002 Sep;297(5588):1867-1870. Pubmedid: 12228717.


• Friberg M, Jennings R, Alsarraj M, Dessureault S, Cantor A, Extermann M, Munn DH, Antonia SJ, Mellor AL. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer. 2002 Sep;101(2):151-155. Pubmedid: 12209992.


• Sotomayor MG, Yu H, Antonia S, Sotomayor EM, Pardoll DM. Advances in gene therapy for malignant melanoma. Cancer Control. 2002 Jan;9(1):39-48. Pubmedid: 11907465.


• Antonia S, Seigne J, Diaz J, Muro-Cacho C, Extermann M, Farmelo M, Friberg M, Alsarraj M, Mahany J, Pow-Sang J, Cantor A, Janssen W. Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J Urol. 2002;167(5):1995-2000. Pubmedid: 11956426.


• Fishman M, Seigne J, Antonia S. Novel therapies for renal cell carcinoma. Expert Opin Investig Drugs. 2001;10(6):1033-1044. Pubmedid: 11772233.


• Antonia SJ, Sotomayor E. Gene therapy for lung cancer. Curr Opin Oncol. 2000 Mar;12(2):138-142. Pubmedid: 10750725.


• Antonia S, Seigne J. B7-1 gene-modified autologous tumor-cell vaccines for renal-cell carcinoma. World J Urol. 2000;18(2):157-163. Pubmedid: 10854153.


• Jackson R, Antonia S, Wright K, Moon S, Nepvue A, Munoz-Antonia T. Human cut-like repressor protein binds TGFbeta type II receptor gene promoter. Arch Biochem Biophys. 1999;371(2):290-300. Pubmedid: 10545217.


• Antonia S. Tumor cell vaccines for renal cell carcinoma. Cancer Control. 1999;6(6):608-611. Pubmedid: 10756394.


• Jennings R, Munoz-Antonia T, Zhu Z, Jackson R, Antonia S. Identification of an enhancer element in the mouse B7-1 promoter. Immunogenetics. 1999;50(1-2):109-112. Pubmedid: 10541818.


• Reintgen D, Antonia S. Immunotherapy: the next major advents. Skin Cancer Foundation Journal. 1999;42:41-44. Pubmedid: noPMID.


• Antonia S. B7-1 gene-modified tumor cell vaccines. Curr Opin Mol Ther. 1999;1(1):50-56. Pubmedid: 11249684.


• Antonia S, Extermann M, Flavell R. Immunologic nonresponsiveness to tumors. Critical Rev Onco. 1998;9:35-41. Pubmedid: 9754446.


• Antonia S, Ruckdeschel J. Improving our management of non-small-cell lung cancer and mesothelioma. Cancer Control. 1997;4(4):293-293. Pubmedid: 10763034.


• Munoz-Antonia T, Xiaochuan L, Reiss M, Rosalind J, Antonia S. A mutation in the transforming growth factor (beta) type II receptor gene promoter associated with loss of gene expression. Cancer Res. 1996;56:4831-4835. Pubmedid: 8895728.


• Jackson R, Antonia S, Nepvue A, Munoz-Antonia T. A mutation in the transforming growth factor beta type II receptor gene promoter associated with loss of gene expression. Arch Biochem Biophys. 1996;56(21):4831-4835.


• Rabb H, Ramirez G, Saba S, Reynolds D, Xu J, Flavell R, Antonia S. Renal ischemic-reperfusion injury in L-selectin-deficient mice. Am J Physiol. 1996;271:F408-F413. Pubmedid: 8770173.


• Antonia S, Finley C, Munoz-Antonia T. Cloning and partial characterization of the mouse B7-1 promoter. Immunogenetics. 1996;43:234-237. Pubmedid: 8575824.


• Antonia S, Wagner, Jr. H, Williams, Jr. C, Alberts W, Hubbell D, Robinson L, Hilstro J, Ruckdeschel J. Concurrent paclitaxel/cisplatin with thoracic radiation in patients with stage IIIA/B non-small cell carcinoma of the lung. Semin Oncol. 1995;22(4):34-37. Pubmedid: 7644926.


• Garrogue-Antar L, Munoz-Antonia T, Antonia S, Gesmond J, Vellucci V, Reiss M. Missense Mutations of the transforming growth factor (beta) type II receptor in human head and neck squamous carcinoma cells. Cancer Res. 1995;55:3982-3987. Pubmedid: 7664267.


• Antonia S, Geiger T, Miller J, Flavell R. Mechanisms of immune tolerance induction through the thymic expression of a peripheral tissue-specific protein. Int Immunol. 1995;5:715-725. Pubmedid: 7547699.


• Antonia S, Munoz-Antonia T, Soldevilla G, Miller J, Flavell R. B7-1 expression by a non-antigen presenting cell-derived tumor. Cancer Res. 1995;55:2253-2256. Pubmedid: 7538898.


• Garland L, Ruckdeschel J, Wagner, Jr. H, Williams, Jr. C, Shaw G, Antonia S, Heise M, Hilstro J, Cantor A. Single agent paclitaxel as second-line chemotherapy for resistant, metastatic non-small cell lung cancer. In: Johnson, Klastersky, eds. Taxanes in Lung Cancer Therapy. New York, NY: Marcel Dekker; 1998;117-126.


• Antonia S, Robinson L, Ruckdeschel J, Wagner, Jr. H. Lung cancer treatment in the older patient. In: Balducci L, Lyman G, Ershler W, et al, eds. Comprehensive geriatric oncology. 2 ed. London. Harwood Academic Publishers; 1998;611-628.


• Simon G, Ruckdeschel J, Williams C, Cantor A, Antonia S, Haura E, Rocha C, Chiappori A, Wagner H, Robinson L, Sommers E, Alberts M, Bepler G. Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institution. Cancer Control. 10(5):388-395. Pubmedid: 14581894.


• Antonia S, Elliott E, Guerder S, Picarella D, Flavell R. Analysis of the immune system utilizing transgenesis and targeted mutagenesis. In: Bluethmann H, Ohashi P, eds. Studies of Tolerance, Inflammation, and Auto Immunity in Transgenic Mice. Academic Press; 1993.

Dr. Scott Antonia serves as department chair and program leader, Thoracic Oncology and program leader of the Immunology Program at Moffitt Cancer Center.  He is a professor of oncology at the University of South Florida College of Medicine.

Dr. Antonia’s research and clinical interests focus on immunotherapy and immunobiology, in particular gene-modified tumor cell vaccine trials at both pre-clinical and clinical stages.  He has designed and conducted numerous cutting-edge studies with novel immunotherapeutics and has two patents for technology he has developed. He has been awarded a K24 grant from the National Cancer Institute to support his clinical research and is the principal investigator for a Thoracic SPORE project.

Dr. Antonia received both his medical degree and a doctorate in immunology from the University of Connecticut Health Center.  He completed an internal medicine residency at Yale University School of Medicine and pursued additional training at Yale through a medical oncology fellowship and post-doctoral fellowship in immunobiology.

Dr. Antonia joined Moffitt in 1994.  Prior to being named chair of Thoracic Oncology in 2010, he was associate chairman of the Sarcoma Department.  Dr. Antonia also serves as chairman of Moffitt’s Scientific Review Committee and medical director of the Tumor Vaccine Production Facility at Moffitt.  He was named the Moffitt Physician of the Year in 2005 and Mentor of the Year in 2008.